Preventing and treating secondary bacterial infections with antiviral agents
Identifieur interne : 000632 ( Ncbi/Merge ); précédent : 000631; suivant : 000633Preventing and treating secondary bacterial infections with antiviral agents
Auteurs : Jonathan A. MccullersSource :
- Antiviral therapy [ 1359-6535 ] ; 2011.
Abstract
Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of influenza. The association of secondary bacterial pathogens with fatal pneumonia during the recent H1N1 influenza pandemic highlights the need for new development in this area. Basic and clinical research into viral-bacterial interactions over the last decade has revealed several mechanisms that underlie this synergism. By applying these insights to antiviral drug development, the potential exists to improve outcomes by means other than direct inhibition of the virus.
Url:
DOI: 10.3851/IMP1730
PubMed: 21447860
PubMed Central: 4907367
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000891
- to stream Pmc, to step Curation: 000891
- to stream Pmc, to step Checkpoint: 000789
Links to Exploration step
PMC:4907367Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Preventing and treating secondary bacterial infections with antiviral agents</title><author><name sortKey="Mccullers, Jonathan A" sort="Mccullers, Jonathan A" uniqKey="Mccullers J" first="Jonathan A." last="Mccullers">Jonathan A. Mccullers</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">21447860</idno><idno type="pmc">4907367</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907367</idno><idno type="RBID">PMC:4907367</idno><idno type="doi">10.3851/IMP1730</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">000891</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000891</idno><idno type="wicri:Area/Pmc/Curation">000891</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000891</idno><idno type="wicri:Area/Pmc/Checkpoint">000789</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000789</idno><idno type="wicri:Area/Ncbi/Merge">000632</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Preventing and treating secondary bacterial infections with antiviral agents</title><author><name sortKey="Mccullers, Jonathan A" sort="Mccullers, Jonathan A" uniqKey="Mccullers J" first="Jonathan A." last="Mccullers">Jonathan A. Mccullers</name></author></analytic><series><title level="j">Antiviral therapy</title><idno type="ISSN">1359-6535</idno><idno type="eISSN">2040-2058</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Summary</title><p id="P1">Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of influenza. The association of secondary bacterial pathogens with fatal pneumonia during the recent H1N1 influenza pandemic highlights the need for new development in this area. Basic and clinical research into viral-bacterial interactions over the last decade has revealed several mechanisms that underlie this synergism. By applying these insights to antiviral drug development, the potential exists to improve outcomes by means other than direct inhibition of the virus.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">9815705</journal-id><journal-id journal-id-type="pubmed-jr-id">21447</journal-id><journal-id journal-id-type="nlm-ta">Antivir Ther</journal-id><journal-id journal-id-type="iso-abbrev">Antivir. Ther. (Lond.)</journal-id><journal-title-group><journal-title>Antiviral therapy</journal-title></journal-title-group><issn pub-type="ppub">1359-6535</issn><issn pub-type="epub">2040-2058</issn></journal-meta><article-meta><article-id pub-id-type="pmid">21447860</article-id><article-id pub-id-type="pmc">4907367</article-id><article-id pub-id-type="doi">10.3851/IMP1730</article-id><article-id pub-id-type="manuscript">NIHMS790592</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Preventing and treating secondary bacterial infections with antiviral agents</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>McCullers</surname><given-names>Jonathan A.</given-names></name><email>jon.mccullers@stjude.org</email><aff id="A1">Department of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA, p: (901) 595-5164, f: (901) 595-3099</aff></contrib></contrib-group><pub-date pub-type="nihms-submitted"><day>28</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>6</month><year>2016</year></pub-date><volume>16</volume><issue>2</issue><fpage>123</fpage><lpage>135</lpage><pmc-comment>elocation-id from pubmed: 10.3851/IMP1730</pmc-comment>
<abstract><title>Summary</title><p id="P1">Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of influenza. The association of secondary bacterial pathogens with fatal pneumonia during the recent H1N1 influenza pandemic highlights the need for new development in this area. Basic and clinical research into viral-bacterial interactions over the last decade has revealed several mechanisms that underlie this synergism. By applying these insights to antiviral drug development, the potential exists to improve outcomes by means other than direct inhibition of the virus.</p></abstract></article-meta></front></pmc><affiliations><list></list><tree><noCountry><name sortKey="Mccullers, Jonathan A" sort="Mccullers, Jonathan A" uniqKey="Mccullers J" first="Jonathan A." last="Mccullers">Jonathan A. Mccullers</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000632 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000632 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:4907367
|texte= Preventing and treating secondary bacterial infections with antiviral agents
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:21447860" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |